Abstract 1205
Background
The prognosis of patients with advanced non-small cell lung
cancer (NSCLC) and coexisting chronic obstructive pulmonary disease (COPD) is uncertain. In addition, no previous studies have examined whether treating COPD improves the prognosis of such patients.
Methods
We focused our retrospective analysis on advanced NSCLC
patients who had received chemotherapy at Kyoto University Hospital between 2007 and 2014. The association between COPD treatment and overall survival (OS) was assessed using the log-rank test and Cox logistic regression models adjusted for age, sex, smoking, chemotherapy, the percentage forced expiratory volume in 1 second (%FEV1.0), and COPD treatment.
Results
Of the 358 patients enrolled, 104 had COPD (COPD group) and
254 did not (non-COPD group). Thirty-seven patients in the COPD group had received COPD treatment. The median OS period was 323 days in the COPD group and 510 days in the non-COPD group (p
Conclusions
Coexisting COPD was associated with worse survival
outcomes in patients with advanced NSCLC. Our analysis indicated that COPD treatment might have potential to salvage the prognosis of such patients.
Clinical trial identification
Legal entity responsible for the study
Kyoto University
Funding
Kyoto University
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract